The Directors have done well to resist a capital raising last year and now with it generating record operational net cashflows there is absolutely no need to do a capital raising unless it was to partially fund the development of Dipidio.
At least 85% of the current debt of around $NZ300 million doesn't have to be repaid before the end of 2012 - there are no worries unless you think gold is going backwards at a great rate.
- Forums
- ASX - By Stock
- OGC
- finding support
finding support, page-14
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OGC (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online